Latest & greatest articles for covid-19

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on covid-19 or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on covid-19 and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for covid-19

2. COVID-19 rapid evidence summary: Sarilumab for COVID-19

COVID-19 rapid evidence summary: Sarilumab for COVID-19 COVID-19 rapid evidence summary: Sarilumab for COVID-19 Evidence summary Published: 20 January 2021 www.nice.org.uk/guidance/es34 pathways Product overview Product overview The content of this evidence summary was up to date in January 2021. New evidence may have been published since then. See summaries of product characteristics (SPCs), British national formulary (BNF) or the Medicines and Healthcare products Regulatory Agency (MHRA (...) ) or NICE websites for up-to-date prescribing information. Sarilumab is an interleukin-6 inhibitor. It has a marketing authorisation for moderate to severe rheumatoid arthritis in adults whose condition has not responded adequately to 1 or more disease modifying antirheumatic drugs. It is licensed for use in combination with methotrexate, or as monotherapy if methotrexate is inappropriate or not tolerated (see the summaries of product characteristics for sarilumab). Use of sarilumab for COVID-19 is off

2021 NICE COVID-19 rapid evidence summary

3. COVID-19 Strategic Preparedness and Response Plan Operational Planning Guideline

COVID-19 Strategic Preparedness and Response Plan Operational Planning Guideline 1 February 2021 to 31 January 2022 COVID-19 STRATEGIC PREPAREDNESS AND RESPONSE PLAN OPERATIONAL PLANNING GUIDELINE1 February 2021 to 31 January 2022 COVID-19 STRATEGIC PREPAREDNESS AND RESPONSE PLAN OPERATIONAL PLAN COVID-19 STRATEGIC PREPAREDNESS AND RESPONSE PLAN OPERATIONAL PLANNING GUIDELINEiv COVID-19 Strategic preparedness and response plan: Operational planning guideline WHO/WHE/2021.03 © World Health (...) relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/). Suggested citation. WHO COVID-19 Strategic preparedness and response plan: Operational planning guideline. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris?. Sales, rights and licensing

2021 WHO Coronavirus disease (COVID-19) Pandemic

4. Living Review - COVID-19: Remdesivir for Hospitalized Adults

Living Review - COVID-19: Remdesivir for Hospitalized Adults COVID-19: Remdesivir for Hospitalized Adults - A Living Review Talk to the Veterans Crisis Line now An official website of the United States government Here's how you know The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you're connecting to the official website (...) and that any information you provide is encrypted and sent securely. Search HSR&D Search the HSRD website Button to search HSRD Contact us TTY: 711 × We're here anytime, day or night — 24/7 If you are a Veteran in crisis or concerned about one, connect with our caring, qualified responders for confidential help. Many of them are Veterans themselves. Get more resources at . » » » COVID-19: Remdesivir for Hospitalized Adults - A Living Review Health Services Research & Development COVID-19: Remdesivir

2021 Veterans Affairs Evidence-based Synthesis Program Reports

5. Mental health outcomes of adults hospitalized for COVID-19: A living rapid review

Mental health outcomes of adults hospitalized for COVID-19: A living rapid review Talk to the Veterans Crisis Line now An official website of the United States government Here's how you know The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you're connecting to the official website and that any information you provide is encrypted (...) and sent securely. Search HSR&D Search the HSRD website Button to search HSRD Contact us TTY: 711 × We're here anytime, day or night — 24/7 If you are a Veteran in crisis or concerned about one, connect with our caring, qualified responders for confidential help. Many of them are Veterans themselves. Get more resources at . » » » Mental health outcomes of adults hospitalized for COVID-19: A living rapid review Health Services Research & Development Mental health outcomes of adults hospitalized

2021 Veterans Affairs Evidence-based Synthesis Program Reports

6. WHO strategic action and resource requirements to end the acute phase of the COVID-19 pandemic 2021

-General declared the novel coronavirus outbreak a public health emergency of international concern (PHEIC), WHO’s highest level of alarm under international law. As the COVID-19 pandemic evolved, the SPRP was updated in April 2020 to underline the importance of critical aspects of the public health response, and support countries to safely and sustainably transition out of the severe movement restrictions that had been put in place in some countries. As we enter 2021, it is again important that we (...) , technical, and operational reach meant WHO was able to support countries around the world in every aspect of COVID-19 public health response, from surveillance and laboratory testing to maintaining essential health services in the most vulnerable and fragile contexts. This graphic highlights just a small selection of WHO’s work in 2020; for more information see: https://www.who.int/ emergencies/diseases/novel-coronavirus-2019/interactive-timeline 23 United Nations (UN) entities participating in UN

2021 WHO Coronavirus disease (COVID-19) Pandemic

7. COVID-19 Strategic Preparedness and Response Plan

repeating them.viii 1 February 2021 to 31 January 2022 COVID-19 STRATEGIC PREPAREDNESS AND RESPONSE PLAN ABOUT THIS DOCUMENT WHO published the first COVID-19 Strategic preparedness and response plan (SPRP) on 4 February, 2020, four days after the Director-General declared the novel coronavirus outbreak a public health emergency of international concern (PHEIC), WHO’s highest level of alarm under international law. As the COVID-19 pandemic evolved, the SPRP was updated in April 2020 to underline (...) COVID-19 Strategic Preparedness and Response Plan 1 February 2021 to 31 January 2022 COVID-19 STRATEGIC PREPAREDNESS AND RESPONSE PLAN1 February 2021 to 31 January 2022 COVID-19 STRATEGIC PREPAREDNESS AND RESPONSE PLANiv COVID-19 Strategic preparedness and response plan WHO/WHE/2021.02 © World Health Organization 2021 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org

2021 WHO Coronavirus disease (COVID-19) Pandemic

8. Contact tracing in the context of COVID-19

Contact tracing in the context of COVID-19 -1- Contact tracing in the context of COVID-19 Interim guidance 1 February 2021 Introduction Contact tracing – along with robust testing, isolation and care of cases – is a key strategy for interrupting chains of transmission of SARS-CoV-2 and reducing mortality associated with COVID-19 1,2 . The trigger to commence contact tracing is detection of a probable or confirmed case (Figure 1). Individuals who have been in contact with this case (...) to as ‘backward tracing’) is key to detecting unrecognized chains of transmission and common points of exposure. Case investigations may be an efficient way to identify additional contacts at particularly high risk of becoming ill with COVID-19. At population level, source investigations help identify risk factors and allow development of targeted public health and social measures (PHSM). As COVID-19 vaccines begin to deploy in many countries, it remains important to enhance existing public health strategies

2021 WHO Coronavirus disease (COVID-19) Pandemic

9. CTS Information and Guidance for Respiratory Health Care Professionals on COVID 19 Vaccination

. PDF document (People who are at risk of more severe disease or outcomes from COVID-19) Provincial and Territorial vaccination rollout plans While NACI provides guidance on vaccination priorities, vaccination rollout plans are province- and territory- specific. For the latest detailed vaccination rollout plans, visit this website and go to the vaccine page for your province or territory: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus- infection/prevention-risks (...) CTS Information and Guidance for Respiratory Health Care Professionals on COVID 19 Vaccination V-3.0 MARCH 16, 2021 1 This advice is for health care professionals and we cannot answer individual patient queries. Those looking for further information are advised to speak to their physician, who are best placed to answer specific questions. CTS Information and Guidance for Respiratory Health Care Professionals on COVID 19 Vaccination Introduction This Canadian Thoracic Society (CTS) document aims

2021 Canadian Thoracic Society

10. Triaging COVID-19 in the Emergency Department

Triaging COVID-19 in the Emergency Department TRIAGING COVID-19 IN THE EMERGENCY DEPARTMENT An Evidence Review from Penn Medicine’s Center for Evidence-based Practice February 2021 Project director: Nikhil K. Mull, MD (CEP) Lead analyst: Matthew D. Mitchell, PhD (CEP) Clinical review: Eric Bressman, MD (Medicine); S. Ryan Greysen, MD, MHS, MA, FHM (CEP); Kathleen Lee, MD (PPMC); Anna U. Morgan, MD (Medicine) Keywords: COVID-19, Emergency Department, triage EVIDENCE SUMMARY Several published (...) algorithms for appraising disease severity in patients with COVID-19 disease or determining whether they can be safely discharged from the Emergency Department (or both) were identified. None of these algorithms have been validated in clinical studies measuring their impact on patient outcomes. Among those algorithms, there is consensus that patients with low oxygen saturation should not be discharged (thresholds range from oxygen saturation of 91% to 94% without supplemental oxygen). Some

2021 Centre for Evidence-Based Practice, Penn Medicine

11. Allergy, Immunodeficiency, Autoimmunity and COVID-19 Vaccination - Position Statement for health professionals

Allergy, Immunodeficiency, Autoimmunity and COVID-19 Vaccination - Position Statement for health professionals ASCIA HP Position Statement COVID-19 Vaccination - Australasian Society of Clinical Immunology and Allergy (ASCIA) | | ASCIA HP Position Statement COVID-19 Vaccination Introduction Vaccination is an important method to reduce the risk of developing infectious diseases, including COVID-19, caused by infection with the SARS-CoV-2 coronavirus. Immunisation occurs after the vaccine (...) stimulates the immune system to induce antibodies (immunoglobulins) and cellular immunity to protect from severe COVID-19 disease, and possibly reduce the risk of transmission of infection in the community. Whilst public health measures and restrictions that were implemented by the Australian and New Zealand governments since March 2020 have been successful in controlling the COVID-19 pandemic, vaccination programs are required throughout the world, including Australia and New Zealand. COVID-19 vaccines

2021 Australasian Society of Clinical Immunology and Allergy

12. Immunodeficiency, Autoimmunity and COVID-19 Vaccination - Guide for health professionals

Immunodeficiency, Autoimmunity and COVID-19 Vaccination - Guide for health professionals Guide: Immunodeficiency, Autoimmunity and COVID-19 Vaccination - Australasian Society of Clinical Immunology and Allergy (ASCIA) | | Guide: Immunodeficiency, Autoimmunity and COVID-19 Vaccination COVID-19 vaccines listed below are not live-attenuated vaccines and are safe for people with immune system disorders, including immunodeficiency and autoimmune conditions. Pfizer/BioNTech COMIRNATY COVID-19 vaccine (...) ( mRNA-based) has been provisionally approved by the Therapeutic Goods Administration (TGA), part of the Australian Government Department of Health, and by Medsafe in New Zealand for people 16 years and older. AstraZeneca/Oxford COVID-19 vaccine (viral vector) has been provisionally approved by the TGA for people 18 years and older. This vaccine is being manufactured in Australia by CSL Behring. Biocelect/Novavax COVID-19 vaccine (protein subunit) has been granted provisional determination by the TGA

2021 Australasian Society of Clinical Immunology and Allergy

13. Allergy and COVID-19 Vaccination - Guide for health professionals

Allergy and COVID-19 Vaccination - Guide for health professionals Guide: Allergy and COVID-19 Vaccination - Australasian Society of Clinical Immunology and Allergy (ASCIA) | | Guide: Allergy and COVID-19 Vaccination 1. Vaccinate without additional precautions Vaccinate in the community as per national recommendations, with a post-vaccination observation period of 15 minutes . This includes people with: History of allergy, including anaphylaxis to food, drugs, venom, or latex. Allergic (...) conditions, including asthma, atopic dermatitis (eczema) or allergic rhinitis (hay fever). 2. Vaccinate with precautions* Immediate (within four hours) and generalised symptoms of a possible allergic reaction without anaphylaxis to a previous dose of a COVID-19 vaccine. Generalised allergic reaction (without anaphylaxis) to one of the ingredients in the COVID-19 vaccine to be administered (Pfizer-PEG or AstraZeneca-Polysorbate 80). Prior history of anaphylaxis to previous vaccines and/or multiple drugs

2021 Australasian Society of Clinical Immunology and Allergy

14. ASCIA COVID-19 vaccine information

to the COVID-19 outbreak many suppliers of medical products are working to ensure the continuity of supply to patients in Australia and New Zealand, whilst also protecting the health of their employees. ASCIA is monitoring the situation and will post notices on this page from medical product suppliers and authorities, including the National Blood Authority (NBA) and the Theraputic Goods Administration (TGA). NBA response to novel coronavirus TGA amendment to restrict hydroxychloroquine prescribing ARRC (...) ASCIA COVID-19 vaccine information ASCIA COVID-19 Information - Australasian Society of Clinical Immunology and Allergy (ASCIA) | | ASCIA COVID-19 Information | | | | | | | | | | | | COVID-19 vaccine information COVID-19 vaccine information: ASCIA New March 2021 New March 2021 New March 2021 New March 2021 Other ASCIA COVID-19 information for patients, consumers, carers is available at COVID-19 vaccine information: AU and NZ Governments COVID-19 vaccination decision guide for women who

2021 Australasian Society of Clinical Immunology and Allergy

15. Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge Key Highlights from the CTS position statement

Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge Key Highlights from the CTS position statement Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge Key Highlights From the Canadian Thoracic Society (CTS) Position Statement Samir Gupta, MD Jane Batt, MD Toronto, ON, Canada Jean Bourbeau, MD Montreal, QC, Canada Kenneth R. Chapman, MD Andrea (...) , Canada Mohit Bhutani, MD Edmonton, AB, Canada Viral pandemics can quickly overwhelm health system capacity. When a rapid increase in patients with coronavirus disease 2019 (COVID-19) led to ICU bed shortages in Northern Italy 1 and elsewhere, clinicians were forced to make dif?cult ICU resource allocation decisions. Similar surges are now being seen in other parts of the world, including the United States. What Frameworks Are Available to Support Resource Allocation Decisions? Ethical frameworks

2021 Canadian Thoracic Society

16. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Full Text available with Trip Pro

prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847. - - Guan WJ, Ni ZY, Hu Y, et al. ; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. - - Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost. 2020;4(7):1178-1191. - - Show all 95 references MeSH (...) American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly

2021 EvidenceUpdates

17. Clinical applications of detecting IgG, IgM, or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review Full Text available with Trip Pro

Clinical applications of detecting IgG, IgM, or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review Clinical applications of detecting IgG, IgM or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging (...) Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Int J Infect Dis Actions . 2021 Jan 12;104:415-422. doi: 10.1016/j.ijid.2021.01.016. Online ahead of print. Clinical applications of detecting IgG, IgM or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review , , , , , Affiliations Expand Affiliations 1 Department of Otorhinolaryngology, Head and Neck

2021 EvidenceUpdates

18. Mortality, Severity, and Hospital Admission among COVID-19 Patients with ACEI/ARB Use: A Meta-Analysis Stratifying Countries Based on Response to the First Wave of the Pandemic Full Text available with Trip Pro

Mortality, Severity, and Hospital Admission among COVID-19 Patients with ACEI/ARB Use: A Meta-Analysis Stratifying Countries Based on Response to the First Wave of the Pandemic Mortality, Severity, and Hospital Admission among COVID-19 Patients with ACEI/ARB Use: A Meta-Analysis Stratifying Countries Based on Response to the First Wave of the Pandemic - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Show account info Close Account Logged in as: username Search: Search Save Email Send to Display options Display options Format Save citation to file Format: Create file Cancel Email citation Subject: 1 selected item: 33525596 - PubMed To: Format: MeSH and other data Send email Cancel Add to Collections Create a new collection Add to an existing collection Name your collection

2021 EvidenceUpdates

19. Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients Full Text available with Trip Pro

Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly (...) of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Sci Rep Actions . 2021 Feb 5;11(1):3246. doi: 10.1038/s41598-021-81844-x. Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Clinical Pharmacology

2021 EvidenceUpdates

20. What are relevant, feasible and effective approaches to promote acceptance, uptake and adherence to physical distancing measures for COVID-19 prevention and control?

What are relevant, feasible and effective approaches to promote acceptance, uptake and adherence to physical distancing measures for COVID-19 prevention and control? Rebecca E Ryan | Anne Parkhill | Lina Schonfeld | Louisa Walsh | Dianne Lowe | Bronwen Merner | Nami Nelson | Sophie J Hill HEALTH EVIDENCE NETWORK SYNTHESIS REPORT 72 What are relevant, feasible and effective approaches to promote acceptance, uptake and adherence to physical distancing measures for COVID-19 prevention and control (...) ? World Health Organization Regional Office for Europe UN City, Marmorvej 51, DK-2100 Copenhagen Ø, Denmark Tel.: +45 45 33 70 00 Fax: +45 45 33 70 01 Email: eurocontact@who.int Website: www.euro.who.int HEALTH EVIDENCE NETWORK SYNTHESIS REPORT 72Health Evidence Network synthesis report 72 What are relevant, feasible and effective approaches to promote acceptance, uptake and adherence to physical distancing measures for COVID-19 prevention and control? Rebecca E Ryan | Anne Parkhill | Lina Schonfeld

2021 WHO Health Evidence Network